Clinical Pharmacy Specialist-Solid Organ Transplant. Transplant Clinical Pharmacy Section. Organ Transplant Centre of Excellence, King Faisal Specialist Hospital and Research Centre (KFSHRC), P.O. Box 3354, Riyadh, 11211, Kingdom of Saudi Arabia.
Adult Transplant Nephrology, Kidney and Pancreas Health Centre, Organ Transplant Center of Excellence, King Faisal Specialist Hospital and Research Centre, Riyadh, Kingdom of Saudi Arabia.
BMC Infect Dis. 2022 Oct 13;22(1):786. doi: 10.1186/s12879-022-07764-x.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and its resulting disease, coronavirus disease 2019 (COVID-19), has spread to millions of people worldwide. Preliminary data from organ transplant recipients have shown reduced seroconversion rates after the administration of different SARS-CoV-2 vaccination platforms. However, it is unknown whether different vaccination platforms provide different levels of protection against SARS-CoV-2. To answer this question, we prospectively studied 431 kidney and liver transplant recipients (kidney: n = 230; liver: n = 201) who received either the ChAdOx1 vaccine (n = 148) or the BNT-162b2 vaccine (n = 283) and underwent an assessment of immunoglobulin M/immunoglobulin G spike antibody levels. The primary objective of the study is to directly compare the efficacy of two different vaccine platforms in solid organ transplant recipients by measuring of immunoglobulin G (IgG) antibodies against the RBD of the spike protein (anti-RBD) two weeks after first and second doses. Our secondary endpoints were solicited specific local or systemic adverse events within 7 days after the receipt of each dose of the vaccine. There was no difference in the primary outcome between the two vaccine platforms in patients who received two vaccine doses. Unresponsiveness was mainly linked to diabetes. The rate of response after the first dose among younger older patients was significantly larger; however, after the second dose this difference did not persist (p = 0.079). Side effects were similar to those that were observed during the pivotal trials.
严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染及其导致的疾病 2019 年冠状病毒病（COVID-19）已在全球蔓延至数百万人。来自器官移植受者的初步数据显示，不同 SARS-CoV-2 疫苗接种平台接种后血清转化率降低。然而，不同的疫苗接种平台是否能提供针对 SARS-CoV-2 的不同保护水平尚不清楚。为了回答这个问题，我们前瞻性地研究了 431 例接受 ChAdOx1 疫苗（n=148）或 BNT-162b2 疫苗（n=283）的肾和肝移植受者（肾：n=230；肝：n=201），并对免疫球蛋白 M/免疫球蛋白 G 刺突蛋白抗体水平进行了评估。该研究的主要目的是通过测量两周后两次接种第一和第二剂疫苗后针对刺突蛋白 RBD 的 IgG 抗体（抗-RBD），直接比较两种不同疫苗平台在实体器官移植受者中的疗效。我们的次要终点是在接受每种疫苗剂量后 7 天内观察到的特定局部或全身不良事件。在接受两剂疫苗的患者中，两种疫苗平台在主要结局方面没有差异。无反应性主要与糖尿病有关。在较年轻的老年患者中，第一次剂量后的反应率明显更大；然而，第二次剂量后这种差异不再持续（p=0.079）。副作用与关键试验中观察到的相似。
